Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZX008 adjunctive therapy in Dravet syndrome with stiripentol background
NL-OMON46127Phase 3Active, not recruiting
- Sponsor
- Zogenix, Inc.
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fenfluramine in Dravet syndrome (4 cohorts), sponsored by Zogenix, Inc. Primary endpoint: Change in mean convulsive seizure frequency per 28 days. Started Dec 2016; status: active, not recruiting.
02
Drugs
fenfluramine
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on NL-OMON46127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46127.